Cardio Diagnostics Seeks Stockholder Nod for Up to $10M Dilutive Issuance at 2026 Annual Meeting
CDIO sits 85% above its 52-week low of $0.97 on light trading volume (0.2× avg).
Summary
Cardio Diagnostics' preliminary proxy seeks stockholder approval to issue up to 5.0 million shares in non-public deals to raise up to $10 million, a potential 169% dilution to fund operations amid ongoing losses and a low stock price.
Key Events · Financing and Capital Events · CDIO
-
2026 Issuance Proposal
Stockholders will vote on authorizing the issuance of up to 5.0 million shares (or convertible securities) in non-public transactions, capped at $10.0 million aggregate proceeds and a maximum 25% discount to market, within three months of approval.
-
Potential Dilution Impact
If all 5.0 million shares are issued, outstanding shares would increase by approximately 169% from the current 2.96 million shares, significantly diluting existing holders.
-
Capital Raise Context
The company has not used prior similar approvals (2023–2025) and has instead relied on an ATM program, which has raised an undisclosed amount. The new proposal provides an alternative capital-raising avenue given the persistently low stock price.
-
Annual Meeting Details
The virtual annual meeting is scheduled for September 18, 2026, with a record date of July 31, 2026. Stockholders will also vote on the election of seven directors and ratification of the auditor.
Analysis · CDIO · Life Sciences
Cardio Diagnostics is asking stockholders to authorize the issuance of up to 5.0 million shares in non-public transactions to raise up to $10 million, with a maximum 25% discount to market. This is a repeat of prior-year proposals that were never used, but the company's ongoing cash burn and reliance on an ATM program make this a critical lifeline. If approved, the issuance could dilute existing holders by roughly 169% based on the current share count, though the actual dilution depends on the terms and amount raised. The company has not yet secured any commitments, and failure to approve could constrain its ability to meet short-term liquidity needs.
At the time of this filing, CDIO was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.97 to $7.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.